Simeprevir: Clinical Trials

7 trials of Simeprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 withdrawn. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Completed 5, Withdrawn 2

Follow Simeprevir: new trials by email Literature Review of Simeprevir trials Research Report on Simeprevir

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)
Daclatasvir + Sofosbuvir, Simeprevir + Sofosbuvir - Hepatitis C, Chronic
Phase 4CompletedFederal University of São Paulo1212015-12-012017-08-01
Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
Simeprevir, Sofosbuvir - PT-NANBH
Phase 4WithdrawnStanford University2015-09-012016-10-13
Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients
Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks - Liver Cirrhosis
Phase 4CompletedAzienda Ospedaliera San Camillo Forlanini2702015-01-012016-03-09
Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
Sofosbuvir, Ribavirin, Pegylated-interferon alfa-2a - Hepatitis C
Phase 4CompletedTanta University100002015-01-012023-08-25
SMV + SOF With/Without RBV for IFN-II Patients With CHC
Simeprevir, Sofosbuvir, Ribavirin - Hepatitis C
Phase 4CompletedSC Liver Research Consortium, LLC242014-10-012018-06-19
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
Sofosbuvir + Simeprevir - Hepatitis C, Chronic, HIV CDC Category A1
Phase 4WithdrawnUniversity of California, San Francisco2014-08-012019-06-13
The SIM-SOF Trial for Hepatitis C
Pegylated Interferon alfa-2b, Simeprevir, Ribavirin - Chronic Hepatitis C
Phase 4CompletedCenter For Hepatitis C, Atlanta, GA932013-12-012016-03-14

Conditions studied

Hepatitis C (4)  ·  Hepatitis C, Chronic (3)  ·  Fibrosis (1)  ·  Liver Cirrhosis (1)

Sponsors

Azienda Ospedaliera San Camillo Forlanini (1)  ·  Center For Hepatitis C, Atlanta, GA (1)  ·  Federal University of São Paulo (1)  ·  SC Liver Research Consortium, LLC (1)  ·  Stanford University (1)  ·  Tanta University (1)  ·  University of California, San Francisco (1)

Countries

United States (4)  ·  Brazil (1)  ·  Egypt (1)  ·  Italy (1)

Top investigators

Adriano M Pellicelli, MD (1)  ·  Anne Luetkemeyer, MD (1)  ·  Asem Elfert, Prof (1)  ·  Brian L Pearlman, MD (1)  ·  Eslam Esmail, Ass Lecturer (1)  ·  Hala M Elsabagh, Prof (1)  ·  Lobna Abo ALi, Ass Prof (1)  ·  Mindie H Nguyen, MD, MAS (1)  ·  Mohamed Elkassas, Lecturer (1)  ·  Paul Pockros, MD (1)  ·  Sabry Abou Saif, Ass Prof (1)  ·  Sherief Abd-Elsalam (1)  ·  Taher Eldemerdash, Prof (1)

Results publications

PMID 24997638, PMID 25557952, PMID 26890629, PMID 27782373, PMID 29535545, PMID 29906601, PMID 32356185